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Abstract 
Background: Plasmodium vivax is the most widely distributed species causing the highest number of malaria cases 
in the world. In Brazil, P. vivax is responsible for approximately 84 % of reported cases. In the absence of a vaccine, con‑
trol strategies are based on the management of cases through rapid diagnosis and adequate treatment, in addition to 
vector control measures. The approaches used to investigate P. vivax resistance to chloroquine (CQ) were exclusively 
in vivo studies because of the difficulty in keeping parasites in continuous in vitro culture. In view of the limita‑
tions related to follow‑up of patients and to assessing the plasma dosage of CQ and its metabolites, an alternative 
approach to monitor chemo‑resistance (QR) is to use molecular markers. Single nucleotide polymorphisms (SNPs) in 
the multidrug resistance gene pvmdr1 are putative determinants of CQ resistance (CQR), but such SNPs in P. vivax iso‑
lates from patients with good response to treatment should be further explored. The aim of this study is to investigate 
the mutations in the gene, supposedly associated to QR, in P. vivax isolates from successfully cured patients, living in 
Brazilian endemic and non‑endemic areas.
Methods: Blood samples were collected from 49 vivax malaria patients from endemic (Amazon Basin: 45) and non‑
endemic (Atlantic Forest: four) Brazilian regions and analysed for SNPs in the CQR‑related P. vivax gene (pvmdr1), using 
PCR‑based methods.
Results: Among the 49 isolates genetically characterized for the gene pvmdr1, 34 (70 %) presented at least one 
mutation. T958M mutant alleles were the most frequent (73 %) followed Y976F (15 %) and F1076L (12 %). Single 
mutation was detected in 24 (70.5 %) isolates and double mutations in ten (29.5 %). The most common single mutant 
genotype was the 958M/Y976/F1076 (79 %), followed by 976F/F1076 (21 %) whereas 958M/Y976/1076L (60 %) and 
976F/1076L (40 %) double mutant genotypes were detected. Single mutant profile was observed only in isolates from 
Amazon Basin, although double mutants were found both in the Amazon and Atlantic Forest regions. Interestingly, 
the genotype 958M/Y976/1076L was present in all isolates from the Atlantic Forest in the Rio de Janeiro State.
Conclusions: Considering that primaquine (PQ) efficacy is highly dependent on concurrent administration of a 
blood schizontocidal agent and that PQ could not circumvent CQR, together with the fact that no pvmdr1 mutation 
should be expected in successfully cured patients, these findings seem to indicate that the pvmdr1 gene is not a 
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Background
Almost 40 % (approximately three billion) of the world’s 
population is presently at risk of contracting malaria. 
The disease causes almost 200 million clinical cases 
and around 600,000 deaths each year [1, 2]. Plasmo-
dium vivax is the most geographically widespread of the 
human malaria parasites, and a serious public health con-
cern in South and Central America, Asia and Southwest 
Pacific [3].
In Brazil, endemic regions are restricted to the Legal 
Amazon (comprising Acre, Amapá, Amazonas, part of 
Maranhão, Mato Grosso, Pará, Rondonia, Roraima and 
Tocantis States), a region that presently accounts for 
99.6  % of the countrywide malaria burden [4]. Plasmo-
dium vivax is the predominant species, responsible for 
84 % of the reported cases [5], PNCM, SVS, MS, unpub-
lished data 2015. Extra-Amazonian autochthonous cases 
account for only 0.04  % of all Brazilian total registered 
and correspond to the autochthonous malaria existing in 
the Atlantic Forest, located along the southeastern Atlan-
tic Coast [6].
Chloroquine resistance (CQR) is the main challenge 
for national malaria control programmes to control vivax 
malaria. The first cases of P. vivax resistant to chloro-
quine (CQ) were described in Papua New Guinea [7] and 
thereafter observed in Indonesia [8], Oceania, Asian [9, 
10] and South American countries, including Brazil [11, 
12]. In Brazil, CQ treatment failures, presumably related 
to CQR, have been reported [13]. The latest 28  day 
in vivo test conducted to assess the efficacy of standard 
supervised CQ therapy in 109 volunteers showed a pro-
portion of 10.1 % of treatment failure (n = 11), despite an 
adequate absorption of CQ in these individuals on day 2 
[14].
Molecular markers can represent a valuable tool for 
monitoring introduction and spread of drug resist-
ance. Contrarily to Plasmodium falciparum, mutations 
at codons in the pfcrt orthologue (pvcg10) gene do not 
seem to mediate CQR in P. vivax [15]. On the other hand, 
the polymorphisms at codons Y976F and F1076L in the 
multidrug-resistant gene 1 (pvmdr1) has been described 
as molecular marker associated to CQR [16]. Indeed, in 
Thailand, Indonesia [17] and Myanmar [18], as well as in 
Mauritania [19] and Cambodia [20], it has been shown 
that 976F mutants were associated with clinical resist-
ance to CQ. In Nepal and India, where P. vivax CQR has 
not been recorded, prevalence of the 976F mutation is 
very low (5 %) [21] or not detected [22], while in India the 
presence of the F1076L mutation was not associated to 
CQR. In addition, in Madagascar, despite 5 % of clinical 
failures more than 90 % of Y976F mutant parasites were 
detected [33].
These polymorphisms also seem to be relatively 
uncommon in Latin America, where P. vivax CQR 
remains relatively infrequent [23]. In Brazil, different 
conclusions were drawn: either mutations in pvmdr1 
were reported in CQ-sensitive P. vivax parasites [24–26] 
or not detected in resistant P. vivax isolates [25, 26], as 
well as P. vivax CQR being associated with pvmdr1 
mutants only in patients with severe malaria [27].
In view of these different epidemiological data, the 
nucleotide polymorphisms (SNPs) of pvmdr1 gene in suc-
cessfully cured vivax malaria patients living in endemic 
(Amazonian) and non-endemic (Extra-Amazonian) Bra-
zilian areas, were investigated in the present study.
Methods
Study site, blood samples and DNA extraction
Blood samples were collected between 2010 and 2014 in 
patients presenting vivax malaria (n =  49) at the Labo-
ratório de Doenças Febris Agudas, INI-IPEC, Fiocruz, 
the Reference Laboratory for Malaria in the Extra-Ama-
zon to the Brazilian Ministry of Health. The inclusion 
criterion was patients with uncomplicated vivax malaria. 
After obtaining informed consent, venous blood collec-
tion was performed according to protocols previously 
approved by the Ethical Research Committees of Fiocruz 
(32839013.6.00005248). Genomic DNA was extracted 
from 1  mL whole blood using QIAamp midi columns, 
as described by the manufacturer (Qiagen). Plasmodium 
vivax samples were diagnosed by microscopic examina-
tion and by polymerase chain reaction (PCR) [28]. All 
patients were treated with CQ plus primaquine (PQ) 
and followed up for 42 days and no treatment failure was 
detected during this period.
PCR and electrophoresis
The pvmdr1 gene was amplified by PCR using gene-
specific primers. The PCR was performed as described 
elsewhere [16, 29] to amplify a partial DNA sequence 
containing three SNPs for pvmdr1 gene including: 
T958M, Y976F and F1076L.
reliable marker of CQR. Further investigations are needed to define a reliable molecular marker for monitoring P. vivax 
CQR in P. vivax populations.
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DNA sequencing and SNP polymorphisms detection
After purification using the Wizard SV Gel and PCR 
Clean-Up System (Promega), the amplified fragments 
were sequenced using Big Dye®  Terminator Cycle 
Sequencing Ready Reaction version 3.1 (Applied Biosys-
tems) and ABI PRISM DNA Analyzer 3730 (Applied Bio-
systems) [30] at the Genomic Platform/PDTIS/Fiocruz. 
The direct DNA sequencing from PCR products was 
compared with the reference wild type Sal I GenBank 
accession nº AY571984 [24, 25]. Forward and reverse 
sequences were analysed using the free software Bioedit 
Sequence Alignment Editor version 7.2.5. Statistical sig-
nificance of differences of pvmdr1 genotypes frequencies 
among Brazilian localities was assessed using Fisher’s 
tests.
Results
The pvmdr1 gene was successfully amplified and DNA 
sequenced in 49 isolates from the Amazon Region (Acre, 
Amazonas, Pará, and Rondonia) and the Extra-Amazo-
nian State of Rio de Janeiro.
Globally, 34 (69  %) showed non-synonymous (958M, 
976F and 1076L) mutations. 958M mutant alleles were 
the more frequent (25/34; 73 %) while 976F (5/34; 15 %) 
and 1076L (10/34; 12  %) were detected at lower fre-
quencies (Table  1). Single mutation was observed in 24 
isolates (70.5  %, 24/34), while double mutations were 
recorded in ten (29.5  %, 10/34) P. vivax samples. In the 
isolates presenting single mutant genotype, the MYF pro-
file was predominant (19/55 %) contrasting with the FF, 
which was found in only five isolates (Table 2).
The pvmdr1 wild-type allele was prevalent in Pará 
(54  %) followed by Acre (40  %), Amazonas (33  %), and 
Rondonia (24  %) states without statistically significant 
difference in proportion (p > 0.05). Single mutants were 
observed only in isolates from the Brazilian Amazon: the 
MFY allele was prevalent in Rondonia (77 %), followed by 
Amazonas (62 %) and Acre (67 %) (p > 0.05), although in 
Pará the FF single mutant was more frequent (66 %) than 
the MYF (p > 0.05). However, when double mutants were 
investigated, samples presenting FL (12  %) and MYL 
(20 %) in both Amazonian and Extra Amazonian States, 
were identified. Irrespective to the Brazilian State FL 
double mutant was the less frequent (Table 2) (p > 0.05). 
Interestingly, all isolates from the Extra Amazon (Rio de 
Janeiro State) showed double mutant genotype (MYL) 
contrasting with those from the Amazon Basin (6  %) 
(p = 0.01), where most of the isolates came from.
Discussion
CQ and PQ remain the drugs of choice to treat vivax 
malaria, but recent studies have reported P. vivax cases of 
resistance to CQ in different regions of the world [9, 31], 
including Brazil [11–13]. Therefore, monitoring the effi-
cacy of CQ in the treatment of vivax malaria is essential 
for early warning systems to promote drug policies.
To circumvent the limitations of in  vivo and in  vitro 
studies and to assess chemo-resistance, identification 
of mutations in target genes has been proposed, such 
as those in the pvmdr1 gene at codons 976 and 1076, as 
well as the increased expression of pvcrto transcripts [12, 
32]. Similar to previous studies performed with samples 
from western Brazilian Amazon [24, 25], in this work 
the T958M mutant was found to be the more frequent 
in the Brazilian Amazon and even in isolates from the 
Extra Amazonian regions. Additionally, in Madagascar 
[33], Nepal [21] and Thailand [34], most of the samples 
Table 1 Frequency of  958M, 976F and  1076L mutants 
in pvmdr1 gene among 49 Brazilian P. vivax isolates
SNPs single nucleotide polymorphisms
SNPs Number of isolates (%)



















Wt Sal1 type 15 (31) 4 5 4 2 0
Single FF 5 (15) 1 4 0 0 0
Double FL 4 (12) 2 0 2 0 0
Single MYF 19 (55) 10 2 5 2 0
Double MYL 6 (18) 0 0 1 1 4
13 (76 %) 6 (54 %) 8 (67 %) 3 (60 %) 4 (100 %)
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presented mutations at 958 position, although all iso-
lates have been obtained from individuals with successful 
response to CQ therapy. No later than November 2015, 
Schousbe and colleagues [35] reported a high prevalence 
of 958M (97.6 %) among P. vivax samples from six differ-
ent geographical sites, suggesting that this allelic variant is 
most likely not associated with CQR and could be an allele 
characteristic of Asia and Africa isolates. The present data 
reinforce the lack of association of 958M with CQR, but 
are not in agreement with Asian and African geographical 
characteristic of this allele, since this allele was present in 
51 % of the Brazilian (South American) samples.
Previous studies seemed to indicate that both SNP and 
amplification of pvmdr1 are associated with variation 
in in  vitro CQ susceptibility of P. vivax [17, 32]. It has 
been shown that the geometric mean of the CQ inhibi-
tory concentration 50  % (IC50) was significantly higher 
in isolates carrying the Y976F mutation when compared 
to wild-type isolates in samples from Indonesia and Thai-
land [17]. However, the clear association between the 
clinical outcome following a three-day CQ treatment and 
non-synonymous mutations in this gene has never been 
demonstrated elsewhere. In fact, the single 976F mutant 
was not very common worldwide (7.4 %) [22], and the FF 
double mutant genotype was detected only in endemic 
regions of three countries: Brazil [36, 37], Honduras [38] 
and Papua New Guinea [39]. In the samples herein ana-
lysed, no significant difference was observed between 
the presence of double 976F/1076L mutant (12  %) and 
single 976F mutant (15  %) and no single 1076L mutant 
was noted. These findings suggest that polymorphisms 
at codons 976 and 1076 may not be strong indicators of 
CQ resistance since all P. vivax isolates were obtained 
from patients with good response to CQ therapy. In addi-
tion, 976F and 1076L mutants were also detected in P. 
vivax isolates in several countries in Africa and in South 
America from patients with no history of CQ recrudes-
cence [23]. Probably, these mutations might have been 
introduced in these countries from Asia where these 
mutations are prevalent [23]. Interestingly, the 976F 
mutation in P. vivax isolates from Extra-Amazonian were 
not detected in areas where autochthonous malaria cases 
from Brazilian Atlantic Forest can occur. Thus, it seems 
that 976F mutations are more associated to geographical 
characteristics than to CQR.
Concerning codon 958, only samples from the Ama-
zon Basin showed the MYF single mutant genotype, and 
double MYL mutants were observed in Amazonas and 
Acre State isolates. On the other hand, all isolates from 
the Extra Amazon State of Rio de Janeiro had the dou-
ble mutant 958+1076 (MYL) genotype and these samples 
were wild type for codon 976. Once again, the hetero-
geneity in these P. vivax populations could reflect the 
genetic diversity rather than an association with CQR in 
endemic areas with different endemic profiles [6].
Considering that pvmdr1 mutations should not be 
expected in CQ-sensitive parasites and that PQ efficacy 
is highly dependent on concurrent administration of a 
blood schizontocidal agent [40] and thus PQ could not 
circumvent CQR, the present findings seem to indicate 
that the pvmdr1 gene is not a reliable marker of CQR.
Conclusion
This study provides new data concerning the molecular 
characterization of P. vivax isolates from Brazilian Atlan-
tic Forest. The SNP diversity observed in samples from 
New World is similar to those from Asia and Africa, and 
probably reflects a capacity for great functional varia-
tion, as already suggested [41]. Very little is known about 
the molecular mechanisms underlying drug resistance 
in P. vivax and most loci that have been suggested to be 
responsible for P. vivax CQR derived from orthologue P. 
falciparum drug CQR genes. Further investigations are 
needed to define a reliable molecular marker for moni-
toring CQR in the Brazilian P. vivax population.
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